MitoQ

Capsida Biotherapeutics emerges from stealth with $140m

Latest articles

Drive to end cancer could pioneer diagnostic technology

Blood test that can determine a cancer signal origin with high accuracy is now available on prescription in the US and could lead to...

Small is mighty when it comes to mitochondria supplements

Optimise, energise, revitalise – MitoQ is on a mission to supplement your mitochondrial health. Coenzyme Q10 – or CoQ10 – is made naturally in the...

Improving speed and accuracy in Alzheimer’s patients

Phase 2a study of patients with Alzheimer's or Parkinson's finds that ANVS401 treatment leads to significant improvement in speed and accuracy. Annovis Bio Inc, a...

New SIRT6 activator supplement hits the market

Sirtuin 6, the protein making waves in the longevity pool, can now be activated by a brand-new supplement. SIRT6 is a protein with an important...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...
fundraising

Editor's picks

Drive to end cancer could pioneer diagnostic technology

Blood test that can determine a cancer signal origin with high accuracy is now available on prescription in the US and could lead to...

Small is mighty when it comes to mitochondria supplements

Optimise, energise, revitalise – MitoQ is on a mission to supplement your mitochondrial health. Coenzyme Q10 – or CoQ10 – is made naturally in the...

Improving speed and accuracy in Alzheimer’s patients

Phase 2a study of patients with Alzheimer's or Parkinson's finds that ANVS401 treatment leads to significant improvement in speed and accuracy. Annovis Bio Inc, a...
MitoQ

Click the globe for translations.

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS disease targets.

Versant Ventures and Westlake Village BioPartners have announced the emergence from stealth mode of Capsida Biotherapeutics Inc, a biotechnology company using an adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases of the central nervous system (CNS) – brain and spinal cord.

Longevity.Technology: In addition to a $50 million series A commitment from the two firms, Capsida has also announced a multi-year strategic collaboration and option agreement with AbbVie that provides $90 million in up front and equity investment capital in addition to potential future option, development and commercial milestone payments. The collaboration is aimed at developing best-in-class, targeted gene therapies for three programmes in serious neurodegenerative diseases.

“Our high-throughput AAV engineering platform is designed to identify differentiated capsids and cargos that will successfully deliver gene therapies with superior cell and tissue targeting and safety profiles than current-generation products in both CNS and non-CNS diseases,” said Robert Cuddihy, MD, CEO of Capsida.

“We are very pleased to debut today with the backing of experienced company creators in Versant and Westlake, as well as with a significant pharma partnership with AbbVie [1].”

A next-generation AAV and cargo platform

Although current gene therapy approaches have shown dramatic efficacy in several rare diseases, the medicines are hindered by imprecise targeting, an inability to transduce a number of cell types and tissues effectively and have safety liabilities. Specifically, most current-generation approaches use naturally occurring serotypes of AAV that have limitations in their ability to transduce desired cell types with a therapeutic gene product. Due to lower transduction efficacy, these products may need to be delivered at higher doses and thus may be more likely to induce immunogenic responses and adverse events.

As a result, many monogenetic and sporadic neurodegenerative disorders remain unaddressed by this therapeutic modality.

Capsida is addressing these concerns with its AAV engineering platform that generates capsids optimised to target specific tissue types and limits transduction of tissues and cell types that are not relevant to the target disease, allowing for improved efficacy and safety. In addition, Capsida is developing proprietary cargo that delivers effective gene replacement or enhancement customised for the specific disease of interest.

The platform originated from ground-breaking research in the laboratory of Viviana Gradinaru, PhD, Professor of Neuroscience and Biological Engineering, Heritage Medical Research Institute Investigator and Director of the Center for Molecular and Cellular Neuroscience at the Tianqiao and Chrissy Chen Institute for Neuroscience at Caltech. The platform uses machine learning, structural biology, non-human primate models and human tissue models to screen billions of engineered capsids for the ability to target desired tissue types precisely.

The company’s engineered capsids have demonstrated markedly enhanced tissue tropism for neurons versus astrocytes, glia and other CNS cell types, thus demonstrating potential to unlock treatments for disorders requiring neuronal transduction that exceeds the performance of first-generation AAV9-based therapies.

“With our long-standing track record in the gene therapy space, it is gratifying to help launch Capsida, which is taking a novel approach to developing genetic medicines,” said Clare Ozawa, PhD, managing director at Versant and a Capsida board member [1].

Collaboration with AbbVie

Capsida’s newly announced collaboration with AbbVie will use the biotech’s platform to identify and advance clinically translatable capsids paired with an innovative therapeutic approach from AbbVie to create tissue-targeted gene therapies for three CNS disease targets.

Under the terms of the agreement, Capsida will receive $80 million up front in cash and a $10 million equity investment. For targets one and two, upon AbbVie exercising its option, Capsida is eligible to receive $530 million in option and development milestone payments excluding commercial milestone payments. Capsida is also eligible to receive up to high single-digit royalty payments on future product sales. Following AbbVie’s exercise of its options for these programmes, AbbVie will be solely responsible for further development and commercialisation.

For the third disease target, upon AbbVie exercising its option, Capsida will have the right to develop through human proof-of-concept and AbbVie would lead late-stage development and commercialisation. Following human-proof-of concept, the parties would enter into a 50/50 cost:profit share with Capsida having the option to co-promote in the US.

For all three programmes, Capsida will lead capsid discovery efforts using its high throughput AAV engineering and screening platform and AbbVie will contribute innovative therapeutic approaches. Capsida will also be responsible for process development and early clinical manufacturing of all programmes.

“We are excited to enter this licensing agreement with Capsida. By combining Capsida’s deep understanding of the structure-function relationship of AAV biology with AbbVie’s innovative cargo therapeutic technologies, we will strive to develop highly effective and transformative gene therapies for patients with devastating CNS disorders,” said Eric Karran, PhD, Vice President, Neuroscience Discovery at AbbVie [1].

Capsida operating plans

Capsida’s initial internal preclinical programmes centre on neurodevelopmental and neurodegenerative disorders, areas in which gene therapies have yet to gain significant traction due to the difficulties of targeting the brain. Based on progress to date, Capsida expects to start IND-enabling work on its first development candidates during 2021 and to start clinical trials in 2022.

In addition to continuing preclinical work on its lead assets, the company plans to use proceeds from its $50 million series A financing to open its state-of-the-art manufacturing facility this year and advance its platform into non-CNS disorders. With the anchor investment from Versant and Westlake and the collaboration with AbbVie, Capsida plans to expand its 50-member team to about 100 scientists this year. To capture the expanding opportunities in the field of gene therapy, Capsida will pursue additional strategic opportunities in parallel with financial investors over the coming months.

[1] https://capsida.com/capsida-biotherapeutics-debut/

Image courtesy of Capsida

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
MitoQ

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
fundraising

Related articles

Calling all longevity start-ups and scale-ups

Some news from us! Longevity.Technology's brand-new investment portal brings innovators and investors together. As a part of our mission to support the companies that will...

Oisín seed raise advances therapies for diseases of aging

Oisín Biotechnologies funding tops $9.5 million, with additional funding set to support preclinical development of its platform and investigational therapy for kidney and other age-related diseases. Seattle-based...

Dorian and HitGen to collaborate on senotherapy

Send in the senoblockers – Dorian and HitGen announce a research collaboration focused on DNA-encoded library-based drug discovery for age-related diseases. HitGen, Inc today announced...

Angermayer’s $120M for the disease of the century

Investor states that mental health issues will be the "number one disease of the 21st century." Fresh from announcing his involvement in a $200 million...

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...
Supps report ad middle